Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Complete Title: PHASE 1/2 STUDY OF BLU-451 IN ADVANCED CANCERS WITH EGFR EXON20 INSERTION MUTATIONS
Trial Phase: I/II
Investigator: Christina Baik
This is a Phase 1/2, open-label study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of single-agent BLU-451. All patients will receive BLU-451 as a single agent administered once daily (QD) or twice daily (BID) on a 21-day treatment cycle.
Keywords:
- Lung Cancer
- Neoplasms
- Lung Carcinoma, Non-Small-Cell (NSCLC)
- Neoplasms, Nerve Tissue
- Adenocarcinoma
- Neoplasms, Bronchial
- Respiratory Tract Diseases
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I/II
Christina Baik
RG1122465
NCT05241873
PHASE 1/2 STUDY OF BLU-451 IN ADVANCED CANCERS WITH EGFR EXON20 INSERTION MUTATIONS
Lung Cancer
Neoplasms
Lung Carcinoma, Non-Small-Cell (NSCLC)
Neoplasms, Nerve Tissue
Adenocarcinoma
Neoplasms, Bronchial
Respiratory Tract Diseases